• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在三联药物联合治疗(有无额外白细胞介素-2)期间,淋巴组织和外周血中HIV有效感染和潜伏感染的动力学。

Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2.

作者信息

Stellbrink H J, Hufert F T, Tenner-Racz K, Lauer J, Schneider C, Albrecht H, Racz P, van Lunzen J

机构信息

Medical Department, University Hospital Eppendorf, Hamburg, Germany.

出版信息

Antivir Ther. 1998;3(4):209-14.

PMID:10682140
Abstract

OBJECTIVE

To study decay rates of productively and latently infected cells in peripheral blood and lymph nodes during triple antiretroviral therapy and the possible impact of interleukin-2 (IL-2) on viral kinetics.

METHODS

In this non-randomized study, nine antiretroviral-naive HIV-positive patients received either saquinavir hard gel capsules 2400 mg three times daily (group I; four patients) or saquinavir soft gel capsules 1200 mg three times daily and IL-2 (group II), in both cases together with two nucleoside analogues. Plasma viraemia and lymphocyte subsets were analysed. Axillary lymph nodes were excised before and after 12 weeks of therapy. Lymph node sections were examined by in situ hybridization for HIV RNA, and productively infected cells were counted. Infection rates of FACS-sorted CD3, CD4 lymph node and peripheral blood mononuclear cells were determined by nested DNA PCR.

RESULTS

Baseline plasma HIV RNA levels ranged from < 25 to > 1 x 10(6) copies/ml and remained undetectable throughout the study in one patient in group I. Plasma viraemia became undetectable after 3 months in four patients (three in group I). Productively infected cells were markedly reduced in the follow-up lymph node specimens. HIV DNA-positive CD4 T cells were reduced in lymphoid tissue and peripheral blood in all six evaluable patients. There were no significant differences between the groups in the clearance rates of plasma virus and of HIV DNA-positive cells.

CONCLUSIONS

Combined antiretroviral therapy rapidly suppressed active HIV replication in plasma and lymphoid tissue. Latently infected cells were cleared at a slower rate. Viral clearance did not appear to be markedly affected by additional IL-2 therapy.

摘要

目的

研究三联抗逆转录病毒治疗期间外周血和淋巴结中高效感染和潜伏感染细胞的衰减率,以及白细胞介素-2(IL-2)对病毒动力学的可能影响。

方法

在这项非随机研究中,9名未接受过抗逆转录病毒治疗的HIV阳性患者,一组(4名患者)每日3次服用2400mg沙奎那韦硬胶囊,另一组(5名患者)每日3次服用1200mg沙奎那韦软胶囊并联合IL-2,两组均同时服用两种核苷类似物。分析血浆病毒血症和淋巴细胞亚群。在治疗12周前后切除腋窝淋巴结。通过原位杂交检测HIV RNA检查淋巴结切片,并对高效感染细胞进行计数。通过巢式DNA PCR测定FACS分选的CD3、CD4淋巴结和外周血单核细胞的感染率。

结果

基线血浆HIV RNA水平范围为<25至>1×10⁶拷贝/ml,在研究期间,I组的1名患者血浆病毒血症始终未检出。4名患者(I组3名)在3个月后血浆病毒血症未检出。随访淋巴结标本中高效感染细胞明显减少。所有6名可评估患者的淋巴组织和外周血中HIV DNA阳性CD4 T细胞均减少。两组之间血浆病毒和HIV DNA阳性细胞的清除率无显著差异。

结论

联合抗逆转录病毒治疗迅速抑制了血浆和淋巴组织中活跃的HIV复制。潜伏感染细胞的清除速度较慢。额外的IL-2治疗似乎并未显著影响病毒清除。

相似文献

1
Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2.在三联药物联合治疗(有无额外白细胞介素-2)期间,淋巴组织和外周血中HIV有效感染和潜伏感染的动力学。
Antivir Ther. 1998;3(4):209-14.
2
Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.接受利托那韦、齐多夫定和扎西他滨三联疗法治疗的初治晚期HIV-1感染患者的病毒载量降低,T淋巴细胞数量增加。
Antivir Ther. 1997 Jul;2(3):175-83.
3
Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.扎西他滨与齐多夫定联合用药对CD4细胞计数在200 - 500个细胞/立方毫米之间的HIV阳性患者的免疫和病毒学活性。
Antivir Ther. 1997 Apr;2(2):105-11.
4
A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.一项针对蛋白酶抑制剂(沙奎那韦)与齐多夫定联合用药,用于先前未经治疗的晚期HIV感染患者的随机对照试验。
Antivir Ther. 1996 Aug;1(3):129-40.
5
A pilot study of a combination of three reverse transcriptase inhibitors in HIV-1 infection.一项关于三种逆转录酶抑制剂联合用于HIV-1感染的初步研究。
Antivir Ther. 1997 Dec;2(4):219-27.
6
The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.接受抗逆转录病毒治疗3年后病毒载量无法检测的患者每日一次服用沙奎那韦/利托那韦的48周疗效。
HIV Med. 2005 Mar;6(2):122-8. doi: 10.1111/j.1468-1293.2005.00274.x.
7
Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).在接受白细胞介素2联合高效抗逆转录病毒治疗(HAART)的晚期HIV疾病患者(CD4细胞计数<200个细胞/mm³)中,每百万外周血单个核细胞的HIV-1前病毒DNA较仅接受HAART治疗的患者有所增加(ANRS - 082试验)。
Antivir Ther. 2003 Jun;8(3):233-7.
8
Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.每日两次服用沙奎那韦软胶囊(SGC),联合或不联合奈非那韦,以及每日三次服用沙奎那韦-SGC,用于HIV感染三联联合治疗的长期疗效和安全性:100周随访
Antivir Ther. 2003 Feb;8(1):37-42.
9
Significant reduction in HIV-1 plasma viral load but not in proviral infected cells during sub-optimal antiretroviral therapy.在次优抗逆转录病毒治疗期间,HIV-1血浆病毒载量显著降低,但原病毒感染细胞数量未减少。
J Biol Regul Homeost Agents. 2000 Jan-Mar;14(1):1-3.
10
HIV-1 DNA and RNA kinetics in primary HIV infection.原发性HIV感染中HIV-1 DNA和RNA的动力学
J Biol Regul Homeost Agents. 2002 Jan-Mar;16(1):49-52.

引用本文的文献

1
Nuclear Transit and HIV LTR Binding of NF-κB Subunits Held by IκB Proteins: Implications for HIV-1 Activation.核转运与 NF-κB 亚基与 IκB 蛋白结合:对 HIV-1 激活的影响。
Viruses. 2019 Dec 16;11(12):1162. doi: 10.3390/v11121162.
2
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.HIV 治愈障碍:靶向和清除 HIV-1 储存库的新方法。
Lancet. 2013 Jun 15;381(9883):2109-17. doi: 10.1016/S0140-6736(13)60104-X. Epub 2013 Mar 29.
3
Targeting IκB proteins for HIV latency activation: the role of individual IκB and NF-κB proteins.
针对 HIV 潜伏期激活的 IκB 蛋白:个体 IκB 和 NF-κB 蛋白的作用。
J Virol. 2013 Apr;87(7):3966-78. doi: 10.1128/JVI.03251-12. Epub 2013 Jan 30.
4
Development of a nonintegrating Rev-dependent lentiviral vector carrying diphtheria toxin A chain and human TRAF6 to target HIV reservoirs.开发一种不整合 Rev 依赖性慢病毒载体,携带白喉毒素 A 链和人 TRAF6,以靶向 HIV 储存库。
Gene Ther. 2010 Sep;17(9):1063-76. doi: 10.1038/gt.2010.53. Epub 2010 Apr 22.
5
Selective killing of HIV-1-positive macrophages and T cells by the Rev-dependent lentivirus carrying anthrolysin O from Bacillus anthracis.携带炭疽芽孢杆菌溶菌素O的Rev依赖性慢病毒对HIV-1阳性巨噬细胞和T细胞的选择性杀伤作用。
Retrovirology. 2008 Apr 25;5:36. doi: 10.1186/1742-4690-5-36.
6
Regulation of HIV-1 latency by T-cell activation.T细胞激活对HIV-1潜伏的调控
Cytokine. 2007 Jul;39(1):63-74. doi: 10.1016/j.cyto.2007.05.017. Epub 2007 Jul 20.
7
Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity.白细胞介素-7和白细胞介素-15对自然杀伤细胞抗人免疫缺陷病毒活性的不同影响。
J Virol. 2004 Jun;78(11):6033-42. doi: 10.1128/JVI.78.11.6033-6042.2004.
8
Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection.慢性HIV-1感染患者在监督性治疗中断期间,已存在的淋巴结定位CD8+T细胞的扩增。
J Clin Invest. 2002 Mar;109(6):837-43. doi: 10.1172/JCI14789.